Table 1.

Tissue concentration of DA and DOPAC/DA in vehicle-treated controls

Brain regionDA (ng/mg protein)DOPAC/DA
Anterior striatum
 Right209.2  ± 6.40.106  ± 0.003
 Left209.3  ± 8.20.104  ± 0.002
Central striatum
 Right169.7  ± 11.90.106  ± 0.004
 Left183.1  ± 11.30.103  ± 0.002
Posterior striatum
 Right139.3  ± 6.10.105  ± 0.006
 Left150.2  ± 6.50.098  ± 0.003
Nucleus accumbens
 Right161.8  ± 12.10.133  ± 0.004
 Left159.6  ± 11.90.128  ± 0.005
Substantia nigra
 Right21.5  ± 3.40.218  ± 0.100
 Left20.6  ± 2.90.222  ± 0.110
  • Values shown are mean ± SEM amounts of DA (nanograms per milligram of protein) and the ratio of the metabolite DOPAC to DA (DA utilization) in the right (injected) and left (noninjected) hemispheres of vehicle-treated controls. No significant differences in DA content were observed after intrastriatal administration of NTN or GDNF. Changes in DA utilization relative to controls are depicted in Figure4C.